REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Recruiting · Phase 3 · NCT07015905
Conditions: Venous Thromboembolism (VTE)
At a glance
- Research payments reported, 2025
- $962,840
- U.S. investigators named
- 12
- Sites paid
- 11
- Planned or actual enrollment
- 2,000
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN7508 (drug), Apixaban (drug), Enoxaparin (drug), Placebo (drug)
- Dates
- Started 2025-06-25; completion 2027-05-12
- Results posted
- Not yet
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $962,840 in research payments for this study in 2025 (1,027 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David B. Hirst, MD Anesthesiology · Riverside, CA
- John R. Schwappach, MD Orthopedic Surgery · Englewood, CO
- Richard D. Berkowitz, M.D. Joint Replacement Surgery · Tamarac, FL
- Chadwick B. Hampton, MD Orthopedic Surgery · Palm Beach Gardens, FL
- Ramiro Nieves, MD Orthopedic Surgery · Miami, FL
- Jose L. Ponce De Leon, M.D. Orthopedic Surgery · Miami, FL
- Edward J. Stolarski, MD Joint Replacement Surgery · Sarasota, FL
- Michael A. Mont, M.D. Joint Replacement Surgery · Baltimore, MD
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
- Felipe D. Gomez, MD Family Medicine · Mission, TX
- Matthew Higgs, M.D. Sports Medicine · Houston, TX
- Daneshvari R. Solanki, FFARCS Anesthesiology · League City, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Phoenix Clinical Research LLC $438,781
- Denver Metro Orthopedics PC $186,570
- $72,729
- Mplusm Consulting LLC $41,076
- Clinical Trials of Texas LLC $40,858
- Cari Clinical Trials $35,108
- Erg Holding Company LLC $30,700
- Futuro Clinical Trials LLC $30,608
- Bioresearch PArtner Holdings Lllp $29,450
- Gulfcoast Research Institute LLC $29,337
- Nextstage Clinical Research LLC $22,522
- Sinai Hospital of Baltimore, MD $5,102
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.